Ask and ye shall receive edition. Within fifteen minutes of mentioning that we hadn’t seen the preemption brief that GSK had filed yesterday in Colacicco, we had a copy of it. As indicated previously, it addresses the SSRI facts of repeated FDA rejection of the warning at issue as scientifically unsubstantiated. Leafing through it, we also recommend it for its discussion of the presumption against preemption.